Oncology Pharmaceuticals Market India    Oncology Pharmaceuticals Market‐India                       August 2011Oncology P...
Executive Summary                     Oncology pharmaceuticals market in India is valued at INR x bn in 20—    Market    ...
•Market Overview•Market Overview•Drivers & Challenges•Government Initiatives•Government Initiatives•Market Value Chain, Re...
Indian oncology pharma market has grown enormously over  the last few years Indian market‐overview                        ...
A huge volume of cancer drugs is exported to many  countries… Exports of Oncological Pharmaceuticals                      ...
Drivers & Challenges ‐ Summary                                                                     Challenges  Drivers    ...
Government initiatives          Reforms in tax structure               Public-Private-partnership                         ...
Public: Domestic Company – Company A  (1/3) Company Information                                                   Offices ...
Public: Domestic Company – Company B (2/3)  Financial Snapshot   i    i lS     h                                          ...
Public: Domestic Company – Company C (3/3) Key Business Segments                                                          ...
Thank you for the attentionThe Oncology Pharmaceuticals  Market – India report is part of Netscribes’ Healthcare Industry ...
Upcoming SlideShare
Loading in …5

Market Research Report : Oncology Pharmaceuticals Market in India


Published on

For the complete report, get in touch with us at : info@netscribes.com
The report begins with the market overview section which provides an insight into the global market, highlighting the market size and growth. It then moves onto the Indian market, with a focus on market size and growth. It also provides import and export figures of cancer drugs in India in terms of value. Regional break-up of the imports and exports have been included.

An analysis of the drivers explains the factors for growth of the industry including increasing cancer cases, changes in the treatment scenario, development of alternative cancer therapies, increasing FDI and increase in the number of cancer health insurances. The key challenges include increased competition, drug patent problems and drug portfolio management problems.

The government initiatives section highlights the PPP R&D projects started in the country. It also analyses the various initiatives undertaken to reduce prices of cancer drugs, the various cancer control programmes implemented and the changes in the custom duty structure.

A brief overview of the drug regulations and patents is presented in the next section. It focuses the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided. The section also provides a list of important patent approvals.

The competition section gives overview of pharmaceutical companies in the country operating in the cardiovascular pharmaceutical industry. The report highlights features of the major players operating in the market in detail. It includes elaborate profile of the major players in the market along with their financial analysis. It also incorporates the recent developments in the Oncology Pharmaceutical industry.

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Market Research Report : Oncology Pharmaceuticals Market in India

  1. 1. Oncology Pharmaceuticals Market India  Oncology Pharmaceuticals Market‐India August 2011Oncology Pharmaceuticals Market in IndiaOncology Pharmaceuticals Market in IndiaApril 2012 1
  2. 2. Executive Summary  Oncology pharmaceuticals market in India is valued at INR x bn in 20— Market  Fourth largest in volume, eighth largest in value in the world market  Market is expected to grow at a CAGR of y% from20‐‐‐‐‐ Drivers: Di Challenges: Ch ll  Increasing number of cancer cases  Increased competition Drivers and   Changes in the treatment scenario  Drug patents problem Challenges  Development of alternative cancer    Drug Portfolio management therapies p  Increase in cancer insurances  Increase in FDI  Reforms in tax structure Government   Reduction in drug prices gp Initiatives  Public –Private Partnership (PPP) programmes  Drug control programmes  Phases of clinical trialDrug regulation  g g  Approval and licensing of drugs Approval and licensing of drugs and patents  Patents  Highly fragmented market with large number of players  Major public players in the market include Company A,Company B, Company C, Company D,  Competition p Company E, Company F, Company G, Company H, Company I, Company J Company E Company F Company G Company H Company I Company J  Major private companies include Company K, Company L, Company M ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPT 2
  3. 3. •Market Overview•Market Overview•Drivers & Challenges•Government Initiatives•Government Initiatives•Market Value Chain, Regulation and  Patents•Competition•Strategic Recommendation St t i R d ti•Appendix ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2011.PPT ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPT 3
  4. 4. Indian oncology pharma market has grown enormously over  the last few years Indian market‐overview Market size INR unit •Fourth largest in volume, eighth largest in  50 value in the world market g 40 m% % •Expected to reach INR y bn in 20‐‐ f 30 e •Cancer is the second largest cause of death in  d 20 b c a the country 10 •According to the National Cancer Registry  •According to the National Cancer Registry 0 Program (NCRP) there are z mn cancer  20‐‐ 20‐‐ 20‐‐e 20‐‐e 20‐‐e 20‐‐e 20‐‐e patients at any point of time •There occurs X cancer related deaths each  Increase in Cancer Cases year In ‘000 •Oral and lung cancer are the most common in  1,200 n% males, while in females, cervical, followed by  1,000 breast and ovarian cancer are the most  800 common 600 y x 400 •Availibilty of xx oncologists per yy people in  200 India 0 20 20‐‐ 20 e 20‐‐eSource: ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPT 4
  5. 5. A huge volume of cancer drugs is exported to many  countries… Exports of Oncological Pharmaceuticals Total Exports  • Highly fragmented market with many domestic  INR units manufacturers lead to huge volume of exports 4,000 e5 • India currently exports to more than 115 countries P% e4 3,000 • Between 20‐‐ ‐ 20‐‐ and 20‐‐ ‐ 20‐‐ the value of export  e3 2,000 of oncology pharmaceuticals rose by m% e2 1,000 e1 • Country A accounted for the highest exports in 20‐‐ ‐ 20‐‐ while Country B ranked highest in 20‐‐ ‐ 20‐‐ 0 20–to 20‐‐ 20– to 20‐‐ 20– to 20‐‐ 20– to 20‐‐ 20– to 20‐‐ Exports – Region wise (20‐‐ ‐ 20‐‐) p g ( ) Exports – Region wise (20‐‐ ‐ 20‐‐) p g ( ) Country A A2% A1% Country B G2% G1% Country C Country C Country D B2% E1% Country E B1% E2% D1% Country F C1% D2% Country G F2% %Source: Ministry of Commerce: Export‐Import Data Bank Note: All figures are for financial year ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPT 5
  6. 6. Drivers & Challenges ‐ Summary Challenges Drivers Increased competition Increasing number of cancer cases Drug patent problems Changes in the treatment scenario Drug portfolio management Development of alternative cancer  D l t f lt ti therapies Lack of affordability Increase in cancer insurances Increase in the amount of FDI ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPT 6
  7. 7. Government initiatives Reforms in tax structure Public-Private-partnership (PPP) projects Government  Initiative Cancer control programmes Reduction in drug prices ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPT 7
  8. 8. Public: Domestic Company – Company A  (1/3) Company Information Offices and Centres – India  X Road Corporate Address Bangalore Tel No. No +91 xx xxxxx xxxxx Fax No. +91 xx xxxxx xxxxx Website www.ppp.com Year of 19-- Incorporation Ticker Symbol xxxxxx Stock Exchange NNN Products and Services Products and Services City A   City A Head Office Category Products/Services CVD, oncology, CNS, respiratory,  Key People Pharmaceutical dermatology, orthopedics, nutritional,  urology, anti‐infectives l ii f i Name Designation Infectious diseases, metabolic diseases,  Person M Founder Molecule  inflammatory/respiratory diseases, and  Person N CFO Development oncology Person O Head Person Q PresidentSource: ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPT 8
  9. 9. Public: Domestic Company – Company B (2/3) Financial Snapshot i i lS h Key Ratios K i Revenue Profit Particulars  y‐o‐y change 20‐‐ 20‐‐ 20‐‐ 20‐‐ INR mn  Revenue INR mn  Profitability Ratios q r Profit / Loss10,000 p Operating Margin s Net Margin n Profit Before Tax Margin 5,000 m n o p 0 Return on Equity t Return on Capital Employed 0 ‐m Return on Working Capital 20‐‐ 20‐‐ 20‐‐ 20‐‐ Return on Assets Financial Summary  Return on Fixed Assets Cost Ratios • The company incurred a net loss of INR xx mn in FY 20‐‐, as  Operating costs (% of Sales) compared to net profit of INR  yy mn in FY 20‐‐ Administration costs (% of  • The company reported total income of  INR xx bn in FY 20‐‐,  Sales) registering an increase of yy per cent over FY 20‐‐ registering an increase of yy per cent over FY 20 Interest costs (% of Sales) Interest costs (% of Sales) Liquidity Ratios • The company earned an operating margin of x per cent in FY 20‐‐ a  Current Ratio decrease of y percentage points over FY 20‐‐ Cash Ratio • The company reported debt to equity ratio of x in FY 20‐‐, an  Leverage Ratios increase of y per cent over FY 20‐‐ Debt to Equity Ratio Financial Summary  Financial Summary Debt to Capital Ratio b i l i Interest Coverage Ratio Indicators Present Value Efficiency Ratios Market Capitalization (INR) X units Fixed Asset Turnover Total Enterprise Value (INR) Y units Asset Turnover EPS (INR) Z units Current Asset Turnover Working Capital Turnover PE Ratio (Absolute) A Capital Employed Turnover Source: Improved Decline ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPT 9
  10. 10. Public: Domestic Company – Company C (3/3) Key Business Segments Key Geographic Segments m n o x y z x x x x x x x y x y y y y y y y z z z z z z z z 20‐‐ 20‐‐ 20‐‐ 20‐‐ 20‐‐ 20‐‐ 20‐‐ 20‐‐ Key Recent Developments Description  i i News • Company A is an integrated research based company that produces a wide range of generic medicines Overview • Serves customers in over 100 countries with manufacturing facilities in several countries Oncology Pharmaceuticals • Products include include Product 1 and Product 2  • Is making consistent effort for continual improvement in rural areas with respect to accessibility of  Key Initiatives medicinesSource: ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPT 10
  11. 11. Thank you for the attentionThe Oncology Pharmaceuticals  Market – India report is part of Netscribes’ Healthcare Industry Series. For more detailed information or customized research requirements please contact:Contact Number: +91 33 4064 6214C N b 91 33 4064 6214E‐Mail: sales@netscribes.comNetscribes (India) Pvt. Ltd. is dedicated to disseminating information and providing quick insights on  hot industries in India and otherNetscribes (India) Pvt Ltd is dedicated to disseminating information and providing quick insights on “hot” industries in India and other emerging markets. Track our new releases and major updates in these industries onAbout NetscribesNetscribes is a knowledge‐consulting and solutions firm with clientele across the globe. The company’s expertise spans areas of investment &  g g f g p y p p fbusiness research, business & corporate intelligence, content‐management services, and knowledge‐software services. At its core lies a true value proposition that draws upon a vast knowledge base. Netscribes is a one‐stop shop designed to fulfil clients’ profitability and growth objectives.Disclaimer: This report is published for general information only. Although high standards have been used the preparation, Netscribes (India) Disclaimer: This report is published for general information only Although high standards have been used the preparation Netscribes (India)Pvt. Ltd. or “Netscribes” is not responsible for any loss or damage arising from use of this document. This document is the sole property of Netscribes (India) Pvt. Ltd. and prior permission is required for guidelines on reproduction. ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPT 11